How Much Protamine is Enough? Current Evidence and Controversies: A Narrative Review
Downloads
Protamine sulfate remains the standard agent for reversing unfractionated heparin following cardiopulmonary bypass (CPB). Conventional reversal is typically based on a fixed protamine-to-heparin ratio of 1 mg per 100 IU of heparin. However, increasing evidence indicates that this empirical approach may not accurately reflect residual circulating heparin levels at the end of CPB and may result in either inadequate reversal or protamine overdose. Excess protamine administration has been associated with platelet dysfunction, impaired thrombin generation, coagulopathy, and increased postoperative bleeding. This narrative review summarizes current evidence on individualized protamine dosing and discusses major controversies and future directions in precision anticoagulation reversal. A literature search was conducted in PubMed/MEDLINE, Embase, and the Cochrane Library for English-language studies published between 2021 and 2026, with earlier landmark studies included when relevant. Priority was given to randomized controlled trials, pharmacokinetic–pharmacodynamic studies, systematic reviews, and meta-analyses.Current evidence consistently demonstrates that individualized protamine dosing reduces total protamine exposure compared with conventional fixed-ratio protocols while maintaining effective heparin neutralization. Heparin concentration-guided strategies and low-dose protamine protocols have achieved comparable reversal outcomes without increasing postoperative bleeding or transfusion requirements. Pharmacokinetic–pharmacodynamic modeling suggests that a protamine-to-heparin ratio of approximately 0.625:1 may be adequate for most patients, substantially lower than traditional recommendations. Meta-analytic evidence further indicates improved coagulation-related outcomes and fewer bleeding complications with concentration-guided management, although definitive benefits regarding mortality, re-exploration for bleeding, and thrombotic events remain uncertain. Individualized protamine dosing represents a promising approach to optimizing anticoagulation reversal after CPB. Nevertheless, further large, multicenter randomized trials evaluating patient-centered outcomes are required before individualized dosing strategies can be recommended as the universal standard of care.
Boral, B. M., Williams, D. J., & Boral, L. I. (2016). Disseminated intravascular coagulation. American Journal of Clinical Pathology, 146(6), 670–680.
Boer, C., Meesters, M. I., Veerhoek, D., & Vonk, A. B. A. (2018). Anticoagulant and side-effects of protamine in cardiac surgery: A narrative review. British Journal of Anaesthesia, 120(5), 914–927. https://doi.org/10.1016/j.bja.2018.01.023
Boral, B. M., Williams, D. J., & Boral, L. I. (2016). Disseminated intravascular coagulation. American Journal of Clinical Pathology, 146(6), 670–680.
Crivellari, M., Landoni, G., Ursoleo, J. D., Ferrante, L., & Oriani, A. (2024). Protamine and heparin interactions: A narrative review. Annals of Cardiac Anaesthesia, 27(3), 202.
Garvin, S., FitzGerald, D. C., Despotis, G., Shekar, P., & Body, S. C. (2010). Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesthesia & Analgesia, 111(4), 849–855. https://doi.org/10.1213/ANE.0b013e3181b79d09
Gkiouliava, A., Argiriadou, H., Antonitsis, P., Goulas, A., Papapostolou, E., Sarridou, D., Karapanagiotidis, G. T., & Anastasiadis, K. (2024). Individualized heparin monitoring and management reduces protamine requirements in cardiac surgery on minimal invasive extracorporeal circulation: A prospective randomized study. Perfusion, 39(8), 1595–1604. https://doi.org/10.1177/02676591231204284
Green, D. (2020). The heparins: Basic and clinical aspects. Academic Press.
Jain, P., Silva-De Las Salas, A., Bedi, K., Lamelas, J., Epstein, R. H., & Fabbro, M., II. (2025). Protamine dosing for heparin reversal after cardiopulmonary bypass: A double-blinded prospective randomized control trial comparing two strategies. Anesthesiology, 142(1), 98–106. https://doi.org/10.1097/ALN.0000000000005256
Lanoiselée, J., Gibert, A., Gouin-Thibault, I., Mansour, A., Pontis, A., Morizot, C., Goset, M., Molliex, S., Morel, J., Noyel, P., Azarnoush, K., Petrosyan, A., Delavenne, X., Zufferey, P. J., & Ollier, E. (2026). Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: A population pharmacokinetic-pharmacodynamic study. British Journal of Anaesthesia, 136(3), 847–855. https://doi.org/10.1016/j.bja.2025.11.057
Lee, T. Y., Hong, S. Bin, Shin, N. Y., & Kwon, J. S. (2015). Social cognitive functioning in prodromal psychosis: A meta-analysis. Schizophrenia Research, 164(1–3), 28–34.
Martinez, B., Baryshnikova, E., Bindi, M. L., & Prisco, D. (2015). Assessment of the effects of antithrombotic drugs. In Point-of-care tests for severe hemorrhage: A manual for diagnosis and treatment (pp. 173–192). Springer.
Meesters, M. I., Koning, N. J., Loer, S. A., & Boer, C. (2017). Clinical decision versus thromboelastometry based fresh frozen plasma transfusion. Enhanced Hemostasis Management Strategies in Cardiac Surgery, 118(3), 191.
Miles, L. F., Burt, C., Arrowsmith, J., McKie, M. A., Villar, S. S., Govender, P., et al. (2021). Optimal protamine dosing after cardiopulmonary bypass: The PRODOSE adaptive randomised controlled trial. PLoS Medicine, 18(6), e1003658. https://doi.org/10.1371/journal.pmed.1003658
Mondal, S., Abuelkasem, E., Vesselinov, R., Henderson, R., Choi, S., Mousa, A., Zaza, K. J., & Tanaka, K. A. (2024). Protamine dosing and its impact in cardiac surgery transfusion practice: A retrospective bi-institutional analysis. Transfusion, 64(3), 467–474. https://doi.org/10.1111/trf.17730
Pathirana, T. I., & Jackson, C. A. (2018). Socioeconomic status and multimorbidity: A systematic review and meta-analysis. Australian and New Zealand Journal of Public Health, 42(2), 186–194.
Raner, G., Hu, Y., Trowbridge, C., Zhang, L., Logan, J., Wu, X., & Zhang, X. (2024). Comparison of blood concentration and weight-based heparin and protamine dosing strategies for cardiopulmonary bypass: A systematic review and meta-analysis. Cureus, 16(2), e54144. https://doi.org/10.7759/cureus.54144
Sedgwick, P. (2015). Meta-analyses: What is heterogeneity? BMJ, 350.
Sharga, B. M., Chromiak, U. I., Pylypiv, D. B., & Feketa, V. P. (2022). Molecular biology practicals.
Sokolowska, E., Kalaska, B., Miklosz, J., & Mogielnicki, A. (2016). The toxicology of heparin reversal with protamine: Past, present and future. Expert Opinion on Drug Metabolism & Toxicology, 12(8), 897–909.
Taylor, M. A., & Maldonado, Y. (2016). Anesthetic management of patients on ECMO. In Extracorporeal membrane oxygenation: Advances in therapy (p. 241).
Wahba, A., Kunst, G., De Somer, F., Kildahl, H. A., Milne, B., Kjellberg, G., et al. (2025). 2024 EACTS/EACTAIC/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. European Journal of Cardio-Thoracic Surgery, 67(2), ezae354. https://doi.org/10.1093/ejcts/ezae354
Copyright (c) 2026 Brillyan T. Jehosua, Anas Alatas

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.





